JAMA

12/18/2025

A conversation between JAMA+ AI Editor in Chief Roy Perlis, MD, MSc, and Associate Editor Yulin Hswen, ScD, MPH. https://ja.ma/3KNvxFY

12/18/2025

💬 Perspective: Early surveillance for the 2025-2026 season suggests A(H3N2) subclade K is becoming dominant, replacing prior H3N2 variants worldwide.

Increasing vaccination coverage and making timely use of antivirals such as neuraminidase inhibitors, as well as considering novel vaccine and antiviral options, are essential strategies to mitigate severe outcomes and reduce influenza transmission.

https://ja.ma/44yEqK6

12/18/2025

Avoidant/restrictive food intake disorder is an eating disorder characterized by avoidance of specific foods and/or restriction of food intake.

This JAMA Patient Page describes avoidant/restrictive food intake disorder and its risk factors, symptoms, diagnosis, and treatment strategies.

https://ja.ma/3L9TSpv

12/18/2025

Among OB/GYN practices in LA County managed networks, fewer than 1 in 10 reachable clinics provided abortion care, and most imposed early gestational limits or out-of-pocket costs, contrary to state law.

Referral pathways varied, with many patients directed to external providers or unable to obtain clear referral information, reflecting ongoing barriers to abortion access for low-income patients within this large, diverse urban population.

https://ja.ma/4p746VD

12/18/2025

For , “timing is everything.”

A new scientific statement from American Heart Association highlights how optimizing circadian rhythm may reduce cardiometabolic disease risk.

Learn why experts say when people sleep, eat, and exercise matters, and how paying attention to individual internal clocks may benefit long-term health.

This Medical News article discusses a new American Heart Association scientific statement on the importance of optimizing one’s circadian system to reduce the risks of obesity, hypertension, type 2 diabetes, and cardiovascular disease.

12/18/2025

Metabolic dysfunction-associated steatotic liver disease, or , is the common “noncommunicable disease you’ve probably never heard of.”

Affecting a third of adults worldwide—especially those with obesity or type 2 diabetes—MASLD often goes undiagnosed until serious complications arise. Timely recognition and intervention are key to improving outcomes.

Read on to learn why experts are calling for greater awareness of MASLD.

This Medical News article discusses the relatively unknown condition called metabolic dysfunction–associated steatotic liver disease, or MASLD, which is thought to affect approximately a third of adults worldwide.

12/18/2025

Individual-level reductions in exposure, achieved through community mitigation, were associated with lower mortality from chronic diseases, including and disease. Larger reductions in arsenic exposure were linked to greater improvements in survival, with benefits sustained over time.

https://ja.ma/4s90tBs

12/17/2025

In this episode of the JAMA Clinical Reviews podcast, JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, speaks with Francesca Celletti, MD, senior advisor on obesity at the World Health Organization, and Ezekiel Emanuel, MD, PhD, of the University of Pennsylvania Department of Medical Ethics and Health Policy, about the new WHO guideline on the use and indications of -1 therapies for the treatment of obesity in adults.

Listen now: https://ja.ma/48TXkwj

12/17/2025

📈 JAMA Guide to Statistics and Methods: Reinforcement learning algorithms, including Q-learning, are used to devise dynamic treatment regimes that adapt to patient responses over time.

Two major Q-learning approaches differ in whether they rely on full patient clinical history or only current clinical state to control for confounding.

Application in observational studies of vasopressin use for shock produced a complex, machine learning–derived regime with potential to improve outcomes but limited clinical interpretability.

https://ja.ma/3Y1Xywr

12/17/2025

📊 Research Summary: Valacyclovir did not improve cognition or function in patients with early symptomatic with HSV seropositivity and is not supported for use in this population.

https://ja.ma/4q5U4Fc

12/17/2025

💬 Editorial: A randomized clinical trial evaluated the efficacy of valacyclovir, an antiviral agent, in patients with mildly symptomatic carrying HSV-1 or amyloid biomarkers.

The study demonstrated no evidence of cognitive benefit and revealed greater cognitive decline in the treatment group compared to placebo.

https://ja.ma/49fXsHO

12/17/2025

The VALAD randomized clinical trial evaluated valacyclovir vs placebo in adults with early symptomatic and herpes simplex virus seropositivity.

Over 78 weeks, valacyclovir was associated with greater cognitive decline compared to placebo and did not provide benefit for functional outcomes or biomarker changes in amyloid or tau.

https://ja.ma/4qfxKJj